The Full Wiki

More info on SR-142,948

SR-142,948: Wikis


Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.


From Wikipedia, the free encyclopedia

Systematic (IUPAC) name
2-([5-(2,6-dimethoxyphenyl)-1-[4-[3-(dimethylamino)propyl-methylcarbamoyl]-2-propan-2-ylphenyl]pyrazole-3-carbonyl]amino)adamantane-2-carboxylic acid
CAS number 184162-64-9
ATC code  ?
PubChem 5311451
Chemical data
Formula C 39H51N5O6  
Mol. mass 685.850 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status
Routes  ?

SR-142,948 is a drug used in scientific research which is a non-peptide antagonist selective for the neurotensin receptors, although not selective between subtypes.[1] It has been used to study the role of neurotensin in the regulation of dopamine receptor activity[2][3][4][5] and glutamate signalling in the brain,[6][7] and in animal studies SR-142,948 blocked the effects of stimulant drugs,[8] including MDMA.[9]


  1. ^ Nalivaiko E, Michaud JC, Soubrié P, Le Fur G (October 1998). "Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons". Neuroscience 86 (3): 799–811. PMID 9692718.  
  2. ^ Alonso R, Gnanadicom H, Fréchin N, Fournier M, Le Fur G, Soubrié P (March 1999). "Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain". The European Journal of Neuroscience 11 (3): 967–74. PMID 10103090.  
  3. ^ Matsuyama S, Higashi H, Maeda H, Greengard P, Nishi A (April 2002). "Neurotensin regulates DARPP-32 thr34 phosphorylation in neostriatal neurons by activation of dopamine D1-type receptors". Journal of Neurochemistry 81 (2): 325–34. PMID 12064480.  
  4. ^ Leonetti M, Brun P, Sotty F, Steinberg R, Soubrié P, Bert L, Renaud B, Suaud-Chagny MF (June 2002). "The neurotensin receptor antagonist SR 142948A blocks the efflux of dopamine evoked in nucleus accumbens by neurotensin ejection into the ventral tegmental area". Naunyn-Schmiedeberg's Archives of Pharmacology 365 (6): 427–33. doi:10.1007/s00210-002-0574-6. PMID 12070755.  
  5. ^ Panayi F, Colussi-Mas J, Lambás-Señas L, Renaud B, Scarna H, Bérod A (May 2005). "Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization". Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology 30 (5): 871–9. doi:10.1038/sj.npp.1300638. PMID 15637639.  
  6. ^ Matsuyama S, Fukui R, Higashi H, Nishi A (September 2003). "Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling". The European Journal of Neuroscience 18 (5): 1247–53. PMID 12956723.  
  7. ^ Yin HH, Adermark L, Lovinger DM (January 2008). "Neurotensin reduces glutamatergic transmission in the dorsolateral striatum via retrograde endocannabinoid signaling". Neuropharmacology 54 (1): 79–86. doi:10.1016/j.neuropharm.2007.06.004. PMID 17675102.  
  8. ^ Reynolds SM, Geisler S, Bérod A, Zahm DS (July 2006). "Neurotensin antagonist acutely and robustly attenuates locomotion that accompanies stimulation of a neurotensin-containing pathway from rostrobasal forebrain to the ventral tegmental area". The European Journal of Neuroscience 24 (1): 188–96. doi:10.1111/j.1460-9568.2006.04791.x. PMID 16882016.  
  9. ^ Marie-Claire C, Palminteri S, Romualdi P, Noble F (June 2008). "Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice". Neuropharmacology 54 (7): 1107–11. doi:10.1016/j.neuropharm.2008.03.001. PMID 18410947.  


Got something to say? Make a comment.
Your name
Your email address